Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.53 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406909 | 1.00 | NOS1 (0.53) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| Hydrochloric Acid SCHEMBL30667970 | 0.98 | NOS1 (0.52) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL30457395 | 0.83 | NOS1 (0.53) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL16339586 | 0.83 | NOS1 (0.53) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL4435758 | 0.74 | NOS1 (0.53) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL21958565 | 0.74 | CHEK1 (0.47) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL29545399 | 0.74 | NOS1 (0.53) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL16371204 | 0.74 | CHEK1 (0.57) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL8296660 | 0.74 | CHEK1 (0.47) | NOS1METAP2CSNK2A1DYRK1ACHEK1 | |
| SCHEMBL30544647 | 0.74 | CHEK1 (0.47) | NOS1METAP2CSNK2A1DYRK1ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705308-A1 | EGFR INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062413-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025235733-A1 | BIS-BICYCLOHETEROARYL MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-3843714-B1 | CD73 INHIBITORS | ARCUS BIOSCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12448375-B2 | Kinase inhibitors for the treatment of neurodegenerative diseases | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1809282-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006044860-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448375-B2 | Kinase inhibitors for the treatment of neurodegenerative diseases | BRDT, BRD3, BRD1 | NOS1 2689/4885METAP2 2587/4885CSNK2A1 633/4885 |
| US-20260062413-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | BRD3, SMN1; SMN2, HDAC1 | NOS1 2673/4885METAP2 3781/4885CSNK2A1 250/4885 |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | NOS1 1566/4885METAP2 2686/4885CSNK2A1 506/4885 |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | NOS1 1115/4885METAP2 2580/4885CSNK2A1 481/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | NOS1 3933/4885METAP2 4182/4885CSNK2A1 743/4885 |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | NOS1 3221/4885METAP2 3861/4885CSNK2A1 902/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | NOS1 1566/4885METAP2 2686/4885CSNK2A1 506/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | NOS1 1566/4885METAP2 2686/4885CSNK2A1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.